Products and medicines - Bristol Myers Squibb
WEBBristol Myers Squibb focuses on developing new medicines to address the unmet medical needs of patients with serious diseases. Explore comprehensive information about our products including dosage and safety information.
Oncology - Bristol Myers Squibb
WEBAs pioneer, Bristol Myers Squibb supported the ground breaking work of Dr. Allison and Dr. Honjo. Based on their luminous insights, we made the first immunotherapy accessible to cancer patients worldwide.
Our research in oncology - Bristol Myers Squibb
WEBAt Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology and neuroscience. Our goal is to empower patients and their loved ones to take back control of their lives.
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb’s …
WEBJun 24, 2022 · Bristol Myers Squibb: Creating a Better Future for People with Cancer. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Transforming cells into cancer fighters - Bristol Myers Squibb
WEBBuilding on our legacy of pioneering transformational science, Bristol Myers Squibb is the first company with two approved chimeric antigen receptor (CAR) T cell therapies in hematologic malignancies with two distinct targets addressing separate blood cancers.
U.S. FDA approves new Bristol Myers cancer immunotherapy
WEBMar 18, 2022 · Bristol Myers Squibb Co (BMY.N) said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBOct 13, 2023 · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon the existing adjuvant indication...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBAug 20, 2021 · Opdivo is now approved in earlier stages of disease for three types of cancer, including the first and only PD-1 inhibitor approved for urothelial carcinoma in the adjuvant setting. PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) 240 mg every two weeks or 480 mg every four weeks ...
Bristol Myers Squibb Products & Medicines
WEBExplore comprehensive information about Bristol Myers Squibb products including dosage and safety information. Learn more about our medicines today.
Medical resources for healthcare providers - bmsmedical.com
WEBClinical and patient resources. Find my Medical Science Liaison (MSL) Identify the appropriate Medical Science Liaison in your area with just a few simple clicks. Find a clinical trial. Explore clinical trials to enroll your patient in. Medical Information Online.
Skip to content